Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

2 papers

Anxiety

Based on 52 papers

Research points to two clear groups of treatments for anxiety. First, ordinary approaches like exercise — especially walking and other regular physical activity — have strong, high-quality evidence showing medium-sized reductions in anxiety symptoms. These are proven in many randomized trials and reviews. Second, newer substance-assisted therapies (often called psychedelic‑assisted therapy) are promising. Small clinical trials and reviews show reductions in anxiety and related problems after carefully supervised doses of drugs such as psilocybin, MDMA, ketamine, and ayahuasca. However, these drug approaches are mostly early-stage or done in special research settings and need more, larger trials before they can become routine care. People thinking about or treating anxiety should know that drug‑assisted therapies are almost always given together with serious psychological support. How the drug is given, the preparation before it, and follow-up therapy matter a lot. There are also safety and equity issues to watch: some psychedelics can have rare lasting side effects, many studies are small, and people of color have been underrepresented in trials. For now, exercise has the clearest and broadest evidence. Other treatments are promising but still need more testing and careful medical oversight.

Key findings

  • Many high-quality reviews find regular physical activity reduces anxiety by a medium amount across many trials. 8792
  • Walking specifically lowers anxiety symptoms compared with doing nothing, based on 26 randomized trials pooled together. 8785
  • Clinical trials and reviews report that psychedelic-assisted therapies (drugs given with therapy) reduced anxiety symptoms in people diagnosed with anxiety disorders. 15068 15063 15056
  • For post‑traumatic stress disorder (a trauma-related anxiety condition), MDMA given with psychotherapy produced large benefits in several controlled trials. 15063
  • Psychedelic drugs appear to change the brain in ways that could help anxiety and mood problems. Lab and imaging studies report increased brain plasticity (the brain’s ability to form new connections) and changes in inflammation and brain networks after substances like psilocybin, DMT, and other psychedelics. 15132 15050 15091 15135
  • Ketamine produces fast antidepressant effects and has been tested as an alternative to electroconvulsive therapy; it has also been studied for anxiety-related conditions in some trials. 10149 10160 15068
  • Most studies of psilocybin and other classic psychedelics are small and done with close medical and psychological support, so experts say larger, well‑controlled trials are still needed before routine use. 15056 15078
  • How people are prepared and supported matters a lot: many guides and reviews agree that screening, setting expectations, building trust, and follow‑up therapy are core parts of substance‑assisted psychotherapy. 15065 15092 15063
  • People of color were underrepresented in many psychedelic-assisted psychotherapy studies, which limits how well the results apply to different ethnic groups. 15095
  • There are risks to be aware of: rare but long-lasting perceptual problems (called HPPD) and other psychological or physical side effects have been reported after hallucinogen use, so safety monitoring is important. 15048 15087

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms

John H. Krystal, Ege T. Kavalali, Lisa M. Monteggia
Neuropsychopharmacology Summary & key facts 2023 188 citations

This review explains how ketamine can lift depression symptoms much faster than standard antidepressants. Researchers describe the clinical results, how doctors usually give ketamine, and the brain changes it seems to cause. They also say that the treatment must be given carefully because small dose changes matter, the exact brain…

Neuroscience and Neuropharmacology Research Treatment of Major Depression Tryptophan and brain disorders Ketamine

Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors

Anastasiya Zaytseva, Evelina Bouckova, McKennon J. Wiles, Madison H. Wustrau, Isabella G. Schmidt, Hadassah Mendez-Vazquez, et al.
eLife Summary & key facts 2023 40 citations

This study used mouse brain cells grown in the lab and live mice to find how low doses of ketamine act quickly to reduce depression-like and anxiety-like behaviors. The researchers found that ketamine lowers activity of a molecule called calcineurin. That change leads to more of a specific kind of…

Neuroscience and Neuropharmacology Research Treatment of Major Depression Tryptophan and brain disorders Ketamine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.